Home » Stocks » RCUS

Arcus Biosciences, Inc. (RCUS)

Stock Price: $32.97 USD -0.92 (-2.71%)
Updated Jul 29, 2021 4:00 PM EDT - Market closed
Market Cap 2.33B
Revenue (ttm) 85.23M
Net Income (ttm) -167.70M
Shares Out 71.00M
EPS (ttm) -2.77
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day July 29
Last Price $32.97
Previous Close $33.89
Change ($) -0.92
Change (%) -2.71%
Day's Open 33.98
Day's Range 32.89 - 34.78
Day's Volume 352,636
52-Week Range 16.69 - 42.36

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

2 weeks ago - Business Wire

Arcus Biosciences, Inc. (RCUS) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further pric...

1 month ago - Zacks Investment Research

No news from Arcus Biosciences is bad news for the company and other industry heavyweights.

1 month ago - The Motley Fool

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

1 month ago - Business Wire

Investors expecting Gilead Sciences to license Arcus Biosciences' lead asset could be in for an unpleasant surprise.

1 month ago - The Motley Fool

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that, at the first ...

1 month ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced initial efficacy an...

2 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -52.11% and -49.68%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

2 months ago - Zacks Investment Research

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results fo...

2 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented progression-free su...

3 months ago - Business Wire

Arcus Biosciences, Inc. (RCUS) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strengt...

4 months ago - Zacks Investment Research

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

4 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today reported financial results fo...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...

5 months ago - Business Wire

Arcus Biosciences Inc. disclosed Monday that Gilead Sciences Inc. boosted its stake in the oncology-focused biopharmaceutical company, through the purchase of $220.35 million worth of stock. Arcus share...

Other stocks mentioned: GILD
5 months ago - Market Watch

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Gilead Science...

5 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today presented preliminary data fr...

6 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that preliminary da...

6 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Andrew Perlman...

6 months ago - Business Wire

Investors need to pay close attention to Arcus Biosciences (RCUS) stock based on the movements in the options market lately.

6 months ago - Zacks Investment Research

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, and WuXi Biologics (2269.HK), a glo...

7 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that management wil...

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that the Compensati...

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced financial results f...

8 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced a collaboration wit...

Other stocks mentioned: AZN
9 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Jennifer Jarre...

9 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

11 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

11 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

11 months ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc.

1 year ago - Business Wire

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

Arcus Biosciences, Inc.: An Oncology Stock With Newfound Prominence

1 year ago - Seeking Alpha

FOSTER CITY, Calif. & HAYWARD, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Arcus Biosciences, Inc. (NYSE: RCUS), an oncology-focused biopharmaceutical company working to create bes...

1 year ago - Business Wire

HAYWARD, Calif.--(BUSINESS WIRE)--Arcus Biosciences, Inc. (NYSE:RCUS), an oncology-focused biopharmaceutical company working to create best-in-class cancer therapies, today announced that Bob Goeltz wil...

1 year ago - Business Wire

Is (RCUS) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Is (RCUS) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Arcus Biosciences (RCUS) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

1 year ago - Zacks Investment Research

The development-stage biopharma is bouncing back from a recent stock dip.

1 year ago - The Motley Fool

Investors expecting a buyout offer were disappointed by the collaboration agreement Gilead Sciences offered.

1 year ago - The Motley Fool

The deal gives Gilead access to a new pipeline of potential cancer immunotherapies.

Other stocks mentioned: GILD
1 year ago - The Motley Fool

Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -12.50% and -12.50%, respectively, for the quarter ended March 2020.

1 year ago - Zacks Investment Research

Is (RCUS) Outperforming Other Medical Stocks This Year?

1 year ago - Zacks Investment Research

Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report.

1 year ago - Zacks Investment Research

Shares of Arcus Biosciences Inc. RCUS, +88.44% soared 87% in trading on Thursday after people familiar with the matter told Bloomberg News that Gilead Sciences Inc.

1 year ago - Market Watch

The two companies are apparently discussing either an equity purchase or some other form of cooperation.

Other stocks mentioned: GILD
1 year ago - The Motley Fool

Arcus Biosciences stock rocketed to a record high Thursday on reports suggesting Gilead Sciences could be interested in acquiring a stake in the Alphabet-backed biotech company.

1 year ago - Investors Business Daily

Does Arcus Biosciences, Inc. (RCUS) have what it takes to be a top stock pick for momentum investors?

1 year ago - Zacks Investment Research

Arcus Biosciences stock is on fire in response to a possible partnership deal with Gilead Sciences.

1 year ago - The Motley Fool

Arcus Biosciences (RCUS) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well

1 year ago - Zacks Investment Research

Arcus Biosciences Anti-TIGIT Candidate Puts Company In The Shop Window

1 year ago - Seeking Alpha

About RCUS

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for monotherapy. The company is also developing Domvanalimab, an anti-TIGIT monoclonal antibody, which is in Phase 2 development for the treatment of first-line metastatic non-small cell lung cancer in combi... [Read more...]

Industry
Biotechnology
IPO Date
Mar 15, 2018
Stock Exchange
NYSE
Ticker Symbol
RCUS
Full Company Profile

Financial Performance

In 2020, RCUS's revenue was $77.52 million, an increase of 416.78% compared to the previous year's $15.00 million. Losses were -$122.86 million, 45.0% more than in 2019.

Financial Statements

Analyst Forecasts

According to 11 analysts, the average rating for RCUS stock is "Strong Buy." The 12-month stock price forecast is 54.00, which is an increase of 63.79% from the latest price.

Price Target
$54.00
(63.79% upside)
Analyst Consensus: Strong Buy